EKF Diagnostics Holdings PLC Investor Presentations

TIDMEKF

EKF Diagnostics Holdings PLC

07 June 2021

EKF Diagnostics Holdings plc

("EKF", the "Company" or the "Group")

Investor Presentations

EKF Diagnostics Holdings plc (AIM: EKF), the AIM-listed point-of-care business, announces that Julian Baines and Mike Salter (who will become Chief Executive Officer on 1 October 2021) will be presenting to institutional investors this week following the recent AGM statement which set out the Company's strategy for growth through to 2024.

No new price sensitive information will be disclosed, and a PDF of the presentation will be made available on the Company's website: https://www.ekfdiagnostics.com/documents-reports.html

 
EKF Diagnostics Holdings plc                                   www.ekfdiagnostics.com 
Christopher Mills, Non-executive Chairman                   Tel: [phone] 
Julian Baines, CEO 
Richard Evans, FD & COO 
 
N+1 Singer                                                         Tel: [phone] 
Aubrey Powell / George Tzimas / Tom 
 Salvesen 
Walbrook PR Limited                   Tel: [phone] or [e-mail] 
Paul McManus / Lianne Cawthorne              Mob: [phone] 
                                                                              391 303 
 
 

About EKF Diagnostics Holdings plc ( www.ekfdiagnostics.com )

EKF is a leading point-of-care diagnostics and central laboratory assay manufacturer with an estimated 80,000 hemoglobin, hematocrit, HbA1c, glucose and lactate analysers in regular use across more than 100 countries. EKF specialises in developing tests for use in anemia and diabetes diagnosis and management, as well as providing a portfolio of reagents for use in clinical chemistry analysers.

EKF specialises in the development, production and worldwide distribution of point-of-care analyzers and clinical chemistry reagents for use in hospital and research laboratories, doctor's offices, blood banks and for in-field anaemia screening programmes. EKF is also a bulk manufacturer of enzymes and has custom manufacturing facilities in the across sites in the US, UK and Europe for a variety of life science products. Demand for contract manufacturing of COVID-19 sample collection tests and kits has grown dramatically during the pandemic, however the capabilities can be applied to other areas of diagnostic testing, molecular disease and forensic test manufacture.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word "Reach" in the source column of the News Explorer pages of London Stock Exchange's website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRADKOBKCBKKAAK

(END) Dow Jones Newswires

June 07, 2021 05:10 ET (09:10 GMT)